NR4A1 and breast cancer: Three-risk group stratification from Oncotype DX RS showed an adjusted HR of 2.5 for distant recurrence (95% CI: 1.30–4.50) between intermediate- vs. low-risk groups and a HR of 5.2 (95% CI: 2.7–10.1) for high- vs. low-risk groups in the node-negative postmenopausal hormonal receptor-positive early breast cancer patients from the TransATAC study population [36].